Twist Bioscience Partners With AWS to Enable AI-Driven Drug Testing Loop
Twist Bioscience is supplying lab synthesis and testing for AWS’s Amazon Bio Discovery platform, linking AI-designed molecules to rapid experimental validation.
AI at work across drug discovery, clinical trials and life sciences.
Research: AIM Research reports on Pharma AI →Page 9
Twist Bioscience is supplying lab synthesis and testing for AWS’s Amazon Bio Discovery platform, linking AI-designed molecules to rapid experimental validation.
Bayer’s CEO says every new drug starts on computers. The pipeline shows AI shifted discovery upstream, but lab validation still defines outcomes.
AI is embedded across clinical workflows in US healthcare, but federal regulation has not caught up. States are stepping in — with fragmented results.
The companies link in silico prediction with organoid validation to improve translational decision-making in drug discovery.
AI can design and run lab experiments, pointing to autonomous research systems that shift scientific bottlenecks from humans to compute.
AI adoption in healthcare is spreading across drug discovery, clinical trials, and patient billing workflows.
CMS has suspended payments to hundreds of Los Angeles hospice providers, using AI-assisted billing analysis to flag suspected fraud.
Phillips Medisize is embedding sensors into single-use systems to enable real-time data capture as drug development shifts to more complex modalities.
At AACR 2026, researchers report a system that identifies social determinants of health from unstructured records with more than 98% accuracy.
Ambience Healthcare introduced a multi-domain AI platform covering care, revenue, and research, building on its documentation tools with expanded workflow capabilities.
Mount Sinai will deploy SOPHiA GENETICS’ AI platform to improve genomic testing, reduce analysis time, and scale cancer diagnostics workflows.
Medline will pilot Symbotic’s AI-powered warehouse system in 2027, marking the first use of the retail-proven technology in healthcare supply chains.
"AI does not create value in isolation; its utility is given by human ingenuity."
As healthcare leaders chase bigger LLMs, revenue cycle teams are achieving 30% denial reduction by narrowing AI scope and adding rigorous governance layers.
Eli Lilly will acquire CrossBridge Bio for up to $300 million as it expands its ADC pipeline alongside investments in AI-driven drug discovery.
Valo Health appoints Chris Anagnostopoulos as Chief Causal AI Officer to scale its human data platform and improve drug discovery outcomes.
Novo Nordisk partners with OpenAI to apply AI across drug discovery, manufacturing, and operations, with full deployment planned by the end of 2026.
TELCOR adds Sample Healthcare’s AI platform to automate administrative workflows in revenue cycle operations with human oversight.
Cleveland Clinic is using Luminai’s AI platform to process and route referrals, aiming to reduce administrative burden and improve workflow efficiency across its system.
Employees are building with AI anyway. The question is whether companies choose to see it.